NicOx S.A. | Cash Flow

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2017
2018
Net Income before Extraordinaries
18,145.00
21,986.00
27,939.00
3,618.00
18,391
Depreciation, Depletion & Amortization
588.00
2,285.00
1,340.00
171.00
136
Other Funds
-
20.00
-
-
198
Funds from Operations
20,440.00
21,653.00
22,143.00
15,044.00
18,057
Changes in Working Capital
1,004.00
11,258.00
138.00
2,634.00
1,086
Net Operating Cash Flow
19,436.00
32,911.00
22,281.00
12,410.00
19,143
Capital Expenditures
605.00
1,614.00
3,831.00
86.00
Sale of Fixed Assets & Businesses
64.00
8,059.00
-
-
Purchase/Sale of Investments
5,255.00
3,201.00
8,885.00
146.00
Net Investing Cash Flow
5,674.00
3,176.00
4,435.00
60.00
Issuance/Reduction of Debt, Net
-
-
179.00
-
Net Financing Cash Flow
-
20.00
24,292.00
25,143.00
Net Change in Cash
25,115.00
29,747.00
6,451.00
12,535.00
Free Cash Flow
19,691.00
33,725.00
22,836.00
12,487.00
Deferred Taxes & Investment Tax Credit
44.00
18.00
35.00
10,850.00
-
Net Assets from Acquisitions
-
-
619.00
-
Other Sources
122.00
-
-
-
Change in Capital Stock
-
-
24,471.00
25,143.00
Exchange Rate Effect
5.00
8.00
5.00
258.00
Other Uses
-
68.00
-
-

About NicOx

View Profile
Address
Drakkar 2 - Bât D
Sophia-Antipolis Provence-Alpes-Cote-dAzur 06560
France
Employees -
Website http://www.nicox.com
Updated 07/08/2019
Nicox SA is an ophthalmology company, which engages in developing innovative solutions to help maintain vision and improve ocular health. Its products include Zerviate, and Vyzulta. The company was founded by Piero Del Soldato, Michele Garufi and Elizabeth Marie Robinson on February 15, 1996 and is headquartered in Sophia-Antipolis, France.